Hikal P/E Ratio
Hikal (HIKAL) P/E ratio is not applicable — EPS (TTM) ₹7.36, 1 consecutive loss quarter. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Consecutive Loss Quarters: 1
Current EPS: ₹7.36
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Sept 2025 | -2.83 | -35 | Loss |
| Mar 2025 | 4.07 | 50 | Profit |
| Jun 2025 | -1.82 | -22 | Loss |
| Dec 2025 | -0.48 | -6 | Loss |
| Sept 2024 | 1.48 | 18 | Profit |
| Mar 2024 | 2.76 | 34 | Profit |
| Jun 2024 | 0.41 | 5 | Profit |
| Dec 2024 | 1.39 | 17 | Profit |
Healthcare Peers with Valid P/E Ratios — HIKAL Comparison
Healthcare sector average P/E 49.05, median 29.34 — HIKAL excluded (negative EPS).
Sector Average PE
49.05
Sector Median PE
29.34
Lowest PE
0.97
Profitable Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 0.97 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.13 | ₹53 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.39 | ₹7,561 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.61 | ₹1,146 | Low |
| Amwill Health Care | AMWILL | 6.04 | ₹65 | Low |
| Mono Pharmacare | MONOPHARMA | 6.85 | ₹20 | Low |
| Medicamen Organics | MEDIORG | 6.94 | ₹28 | Low |
| Brooks Laboratories | BROOKS | 7.38 | ₹166 | Low |
| Shelter Pharma | SHELTER | 7.4 | ₹54 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Hikal share price screener.
- Browse HIKAL balance sheet details for revenue, profit, balance sheet and cash flow data.
- Analyse HIKAL FII DII holdings to track promoter, FII and institutional holdings.